NEULAND LABORATORIES
|
The Current P/E Ratio of NEULAND LABORATORIES is 51.34.
| Share Price | ₹19,964.7 | Aug 05,2026 |
| Market Cap | ₹25,554.8 Cr | |
| Earnings-TTM | ₹497.8 Cr | TTM-Consolidated Results |
| Price/Earnings | 51.34x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of NEULAND LABORATORIES
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹25,554.8 Cr] as on Aug 05,2026
(/) Earnings [ ₹497.8 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 51.34x ]
Thus, for NEULAND LABORATORIES , the investors are currently willing to pay 51.34 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of NEULAND LABORATORIES !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of NEULAND LABORATORIES over the last five years.
Historical PE (Price/Earnings) ratio chart of NEULAND LABORATORIES
PE Ratio Performance Analysis for NEULAND LABORATORIES
- NEULAND LABORATORIES 's p/e ratio for fiscal years ending Mar2026 to Mar2022 averaged 32.71x.
- NEULAND LABORATORIES 's operated at median p/e ratio of 26.86x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, NEULAND LABORATORIES 's p/e ratio peaked in Mar2025 at 59.57x.
- NEULAND LABORATORIES 's p/e ratio hit its five-year low in Mar2023 of 14.12x.
How does NEULAND LABORATORIES 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| NEULAND LABORATORIES | 497.77 | 51.34 | 25,554.8 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 12,172.70 | 38.42 | 467,630.0 |
| DIVIS LABORATORIES LTD | 2,925.00 | 75.78 | 221,666.0 |
| TORRENT PHARMACEUTICALS LTD | 2,156.00 | 88.18 | 190,108.0 |
| CIPLA LTD | 3,364.84 | 34.81 | 117,139.0 |
| DR REDDYS LABORATORIES LTD | 3,169.30 | 30.92 | 97,990.9 |
| MANKIND PHARMA LTD | 2,055.11 | 49.28 | 101,267.0 |
| LUPIN LTD | 5,355.47 | 20.37 | 109,096.0 |
| ZYDUS LIFESCIENCES LTD | 5,026.40 | 22.05 | 110,823.0 |
| AUROBINDO PHARMA LTD | 3,501.45 | 26.51 | 92,831.5 |
| LAURUS LABS LTD | 1,090.76 | 91.28 | 99,563.3 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs NEULAND LABORATORIES 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 20.37x |
| Max industry PE | 91.28x |
| Median industry PE | 38.42x |
| Average industry PE | 48.08x |
You may also like the below Video Courses